LATEST NEWS
  •  
    Airport will organize client carriers to meet new IATA standards
    The International Air Transport Assn. (Montreal) has "welcomed" the Brussels Airport "to become the first to become the first European hub for pharmaceutical freight using IATA's global certification program for shipping cold-chain pharmaceuticals," according to a statement. Over the past year, IATA, which represents the majority of air transport (passenger and cargo) capacity globally, established a certification specific to pharmaceutical transport, run by its Center of Excellence for Independent Validators (CEIV)
  •  
    MolecularHealth's RxAssistance evaluates patient access to commercial therapeutics and clinical trials
    It sounds a little gimmicky, but there is real science and informatics behind a new service from MolecularHealth (Woodlands, TX) called RxAssistance. MolecularHealth has already commercialized TreatmentMAP, what it claims to be the largest single panel genetic test, looking for over 500 genetic markers in a patient's tumor. Until now, the physician ordering the $5,000 test would receive an "actionable" report summarizing the genetic findings, and recommending up to three treatment options, based on efficacy and
  •  
    Cloud-based system is intended to focus reps' sales efforts more effectively
    Newly announced Nexxus Mobile Sales (NMS) is the latest in a series of applications for pharma commercialization efforts building off the IMS One cloud-based platform, according to the company. NMS is intended to work with most available salesforce automation (SFA) tools, which are commonly used today by reps to schedule calls, locate physicians and plan weekly or daily schedules. (This would include IMS Health's own 360 Vantage system, which the company acquired in early 2013, now rebranded as Nexxus Sales.) "One of the problems
  •  
    Will federal legislation resolve ongoing DEA/drug-distributor conflicts?
    An indictment from the US Attorney, Northern District of California, over past practices of FedEx in mail-order drug deliveries, announced in July, has been expanded to include money laundering charges. That addition is apparently from FedEx's standard service of collecting payments on behalf of some customers; FedEx's collect on delivery service "is available to all of our millions of FedEx Express customers," Patrick Fitzgerald, a company spokesman, told the Wall Street Journal, while reiterating that FedEx disputes all the charges the Dept. of Justice
  •  
    Meanwhile, a scramble to accelerate vaccine testing ramps up
    Direct Relief, Inc., one of a number of public health nonprofits that responds to disasters and other healthcare crises, is organizing a shipment of more than 40 tons of essential medicines and supplies to support healthcare workers trying to manage the Ebola outbreak, now affecting several countries in West Africa. The death toll has passed 1,000 (and is thought to be significantly undercounted) and the latest reports from the World Health Organisation say that it could last months. This latest shipment from Direct Relief (there has been at least one prior delivery) includes 2.3 million gloves, 65,000 masks, 92,000 gowns, and 185,000 tabs of antibiotics
  •  
    Three times as many manufacturers expect more 3PL use as expect less; 38% see no change
    A survey conducted by Sonoco ThermoSafe, one of the leading providers of passive packaging for life sciences products, shows that industry managers place performance above cost as a container-selection qualification, are looking to increase their usage of third-party logistics (3PLs) providers, and are increasingly factoring in environmental concerns with recyclability and reuse of the containers. Preliminary results are based on 165 respondents both who were both personally interviewed and who filled out an online survey. Pharmaceutical Commerce's editor in chief, Nick Basta, was part of
  •  
    Postponement of public data for six months is justified by slow rollout of CMS rules, they say
    The pharma industry, among other life sciences firms, has been busy for most of this year preparing its reports to CMS on payments made to prescribers and some of their hospital affiliations. But over on the physicians' side, near-panic seems to be setting in as the Sept. 30 date for public release of the spending data approaches. A letter (available here; registration required) has been sent to Marilyn Tavenner, CMS Administrator, seeking a six-month publication delay as required by the Open Payments System established under the Physician Payments Sunshine Act. For industry, the challenge is to properly aggregate
  •  
    Outsourced contract-administration provider highlights growth in invoicing and financial stewardship burdens
    It's no secret that managing the basic billing, payment collection and reconciliation of the pharma industry is more complicated today. Even before Obamacare (which is expanding both the number and complexity of billing entities), pharma finance departments were dealing with a bewildering array of federal and state programs, and more complicated fee-and-chargeback arrangements with wholesalers. Add to this the variety of patient-support programs, analysis of coupon programs and other financial arrangements, and the overall picture becomes ever more obscure. Nor should the trend toward more--and bigger--
  •  
    Latest ZS AccessMonitor asks, 'Who are [physicians] listening to?'
    The annual update from ZS Associates (Chicago), a consulting firm on sales and related practices in life sciences, finds that 51% of physicians were considered "accessible" this year, as compared to 55% in 2013. "Though this year's drop was less precipitous than in previous years, it reflects the steady decline in access over the past decade," concludes the report. Data are based on call reports for over 200 pharma sales teams, meeting with approximately 325,000 prescribers. "Accessible" means those who were not either "access restricted" (who met with 31-70% of the reps who called on them) or
  •  
    Pharmaceutical Commerce's latest report finds continued growth in these specialized logistics services
    The 5th edition of the Biopharma Cold Chain Sourcebook analyzes economic, regulatory and technological trends in a vital part of today's industry: the shipment of temperature-controlled products. The just-published report calculates that current (2014) expenditures for commercial shipments will be $8.36 billion, rising to $10.28 billion in 2018. By comparison, last year's Sourcebook estimated the 2013 cold-chain business to be $7.5 billion, rising
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the September/October 2014 Issue now - It's Free!
COLD CHAIN FOCUS
Family of GTS Carry Packs handles drugs that patients self-administer
 
INDUSTRY EVENTS
 
 
 
 
WHAT THEY'RE SAYING
Pharmaceutical Commerce sat down with Angela Miccoli, president of Cegedin Relationship Management NA, to talk about sales force automation, customer relationship management and multichannel marketing. Here’s what she had to say.
 
 
FEATURES
The drive for lower costs, safer products  continued >
 
True 'market access' should involve coordinated approaches to patients and their healthcare providers  continued >
 
MDM practices are moving far beyond compliance concerns  continued >
 
The eye-popping price tag on the hepatitis C drug, from Gilead Sciences, has prompted unprecedented pushback from payers  continued >
 
 
MOST POPULAR STORIES
 
 
SPECIAL FOCUS REPORT
US pharma layoffs do not reflect the industry's health
 
The perverse fascination that the business press has with pharma layoffs masks the industry's underlying strength
 
CLINICAL OPERATIONS
 
 
 
   
  |     |     |     |     |     |  
©2014 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.